<DOC>
	<DOC>NCT00548470</DOC>
	<brief_summary>This is an open label pre-post study of the effects of clinical treatment with varenicline on 1) decreasing smoking in schizophrenic patients, 2) improving selected cognitive measures in schizophrenic patients, and 3) effects nicotinic binding to leukocytes and DNMT1 mRNA in lymphocytes. Patients are assessed on subjective and objective measures of smoking , selected cognitive measures, and special chemical measures, during baseline testing and during 8 weeks of treatment with varenicline ( 1-3 mg/day).</brief_summary>
	<brief_title>Varenicline Effects In Schizophrenic Smokers</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Tobacco Use Disorder</mesh_term>
	<mesh_term>Varenicline</mesh_term>
	<criteria>Clinical Diagnosis of Schizophrenia or Schizoaffective Psychosis Recent History of Cigarette smoking Ages 1865</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>schizophrenia</keyword>
	<keyword>varenicline</keyword>
	<keyword>cognition</keyword>
	<keyword>cigarette smoking</keyword>
</DOC>